New schemes

Brucella, antibodies

EQA scheme Brucella, antibodies, is available again in Labquality’s scheme selection. The scheme is suitable for different assays. Please register as soon as possible in LabScala or through your local distributor.

Norovirus, antigen detection

Labquality is announcing a new EQA scheme for antigen detection of Norovirus using point-of-care testing. Round 1, 2024, will be a pilot study free of charge for a limited number of participants. Please register by 30 June 2024.

Helicobacter pylori, nucleic acid detection

Labquality is announcing a new EQA scheme for nucleic acid detection of Helicobacter pylori. The scheme will be suitable for different methods. Registration for this pilot study is closed.

Maternal serum screening

This EQA scheme for Maternal serum screening is suitable for first and/or second-trimester screenings, including analytes AFP, b-hCG, Inhibin A, PAPP-A, total hCG, and unconjugated Estriol. Registration for this pilot study is closed.

Mycoplasma genitalium, drug resistance multiplex, nucleic acid detection

The scheme is suitable for nucleic acid assays detecting Mycoplasma genitalium and mutations in the 23S rRNA gene that are associated with resistance to azithromycin (macrolide antibiotic). Registration for this pilot study is closed.

Pipette control

This EQA scheme allows clinical laboratories to perform intermediate performance checks between pipette calibration intervals, including interlaboratory comparison and individual performance assessment against a reference measurement value. Registration for this pilot study is closed.

Salivary Cortisol

Labquality is announcing a new EQA scheme for Salivary Cortisol. The scheme is suitable for different assays measuring salivary cortisol in clinical samples. Registration for this pilot study is closed. 

Chemokine CXCL13

Labquality is announcing a new EQA scheme for Chemokine CXCL13, a biomarker for neuroborreliosis. Pilot round includes two samples that should be analysed as regular patient samples. Registration for this pilot study is closed.

Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis

Labquality is announcing a new EQA scheme for Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis. The scheme is suitable for different ELISA assays measuring the cell-mediated response to specific tuberculosis antigens in whole blood. Registration for this pilot study is closed. 

Faecal Elastase

Labquality is announcing a new EQA scheme for faecal elastase. In the pilot study, two lyophilized faecal samples of different elastase concentration will be included. Registration for this pilot study is closed. 

Fungal infections, nucleic acid detection

Labquality is announcing a new EQA scheme for direct nucleic acid detection of fungal infections. The scheme samples may contain yeasts, moulds and dermatophytes and it will be suitable for different nucleic acid test panels. Registration for this pilot study is closed. 

Mycobacterium tuberculosis, rifampicin and isoniazid, nucleic acid detection

Labquality is announcing a new EQA scheme for nucleic acid detection of Mycobacterium tuberculosis, including samples containing rifampicin and isoniazid resistance. The scheme is suitable for nucleic acid test panels, and scoring is based on qualitative interpretation. Registration for this pilot study is closed. 

Adrenocorticothropic hormone ACTH and Cortisol

Labquality is announcing a new pilot study for two hormones ACTH and cortisol. Registration for this pilot study is closed. 

HSV1&2 / VZV / T. pallidum, nucleic acid detection

Labquality is announcing a new pilot study for nucleic acid detection of four pathogens included in a four-plex sample. The included pathogens are HSV1&2, VZV and Treponema pallidum. Registration for this pilot study is closed. 

EQA for next-generation sequencing methods

We are developing external quality assessments for NGS methods in microbiology. If you are interested, please contact us!